Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

Earlier in the week, Mr. Trump said he would also impose a 50-per-cent tariff on copper and 200 per cent on pharmaceuticals – potentially piling even more pressure on a Canadian economy reeling from ...

Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk's patent on its branded drugs Ozempic and Wegovy is set to expire in January. "Canada is a major ...

Hims, a telehealth platform, joins a growing list of drugmakers that are looking to cash in on Novo Nordisk's lapsed patent on its GLP-1s. It's the first time the company will be operating in Canada.